Therapeutic effect of the BPC-157 peptide in the treatment of addiction effects.

Abstract: The peptide BPC-157, exhibiting a broad spectrum of action, also finds its application in treating the effects of addictions and alleviating unwanted symptoms during the withdrawal syndrome of these substances. Therefore, BPC-157, both in parenteral and oral form, can be confidently identified as a precursor helpful in treating various groups of addictions.

Keywords: addiction; non-steroidal anti-inflammatory drugs; BPC-157 therapy; overdose; paracetamol; alcohol addiction; drug addiction; withdrawal syndrome; local anesthetics; opioid drugs; morphine; lidocaine; diclofenac; amphetamine; alcohol

List of abbreviations: BPC- Body Protection Compound; NSAIDs- Non-Steroidal Anti-Inflammatory Drugs. BPC-157 peptide therapy is a precursor therapy that acts on and affects the negative pathological effects caused by addictions to specific substances. BPC-157 therapy allows for combating unwanted effects associated with the abuse of alcohol, drugs, NSAIDs, opioid drugs, and local anesthetics.

Treatment of the Effects of NSAID Addiction

The concept of NSAIDs

NSAIDs are non-steroidal anti-inflammatory drugs, which are the most commonly used agents for pain relief. Their action profile is characterized by analgesic, anti-inflammatory, antipyretic, and antiplatelet effects. Most drugs in this group are available without a prescription, which increases the risk of NSAID addiction. It is a common phenomenon for patients to use several NSAIDs without adequate knowledge of the consequences of such conduct and without medical consultation, which limits control over the safety of their use. Self-medication can lead to addiction to drugs from the NSAID group and serious consequences of such a condition, including changes in the digestive system, kidneys, liver, or respiratory system in patients with asthma. Making the patient aware of how NSAID therapy should be conducted and combating the side effects arising from unskilled, addictive therapy is an important aspect for maintaining and restoring health.

BPC-157 Therapy in Treating the Effects of NSAID Addiction

An example of the effectiveness of BPC-157 peptide therapy in relation to the abuse of NSAIDs is aspirin, otherwise known as acetylsalicylic acid. The action profile of aspirin is based on inhibiting cyclooxygenase activity, thereby preventing the synthesis of prostaglandins, which leads to a reduction in inflammation. The aforementioned effect is a desired one, and the use of aspirin at specified doses and intervals is safe. Other cyclooxygenase inhibitors include ibuprofen, diclofenac, and paracetamol. Unfortunately, these substances are often abused due to their rapid action profile and availability, which carries a serious spectrum of side effects such as nausea, vomiting, stomach ulcers, headaches, disturbances of consciousness, and mood deterioration, as well as the risk of a heart attack or stroke. BPC-157 therapy is a precursor, modern, and safe therapy enabling the treatment of effects caused by addiction to NSAIDs. The action profile of BPC-157 in treating the side effects caused by NSAIDs is based on protein phosphorylation, inhibition of protein denaturation, stabilization of lysosomal and cellular membranes, inhibition of complement activation, inhibition of proteases and protein kinases, and fibrinolytic activity.

Hepatoprotective Action of BPC-157 in NSAID Abuse

The hepatotoxic effects of NSAIDs are also counteracted by BPC-157, particularly in the case of paracetamol, diclofenac, and ibuprofen. The hepatotoxicity of paracetamol in particular is attributed to its conversion into a highly reactive metabolite, N-acetyl-p-benzoquinoneimine (NAPQI), through the action of microsomal enzymes of the P450 family. The action of BPC-157 peptide inhibits or reverses this process. The hepatoprotection of BPC-157 is extensive, acting in both acute and chronic, and even advanced stages of liver disease, and administration of the peptide both parenterally and orally is a practical and convenient option for liver protection. Additionally, in the case of diclofenac or ibuprofen abuse, BPC-157 allows for the recovery of liver function by almost completely normalizing (ALT) or significantly reducing (AST) levels. The action of BPC-157 also includes counteracting portal and hepatogastric hypertension.

BPC-157 Treatment in Cases of Paracetamol Overdose

Studies on paracetamol overdose have demonstrated rapidly induced, progressive hepatic encephalopathy accompanied by seizures and damage in several areas of the brain. BPC-157 therapy is effective in treating paracetamol toxicity. The action of BPC-157 peptide reduces liver and brain damage, particularly when administered immediately after paracetamol. BPC-157 used under conditions of paracetamol addiction eliminated seizures by reducing neuronal activity and interstitial edema without an inflammatory response. These studies demonstrate that BPC-157 peptide, in a safe manner, even in the most advanced states inducing harmful processes caused by paracetamol overdose, will bring the expected positive therapeutic effect.

Treatment of the Effects of Alcohol Addiction

Alcohol Addiction

Alcohol addiction is a commonly occurring phenomenon in every social group. Alcoholic beverages are easily accessible, which can result in alcoholism to a lesser or greater degree. Addiction to or even abuse of alcohol is a chronic, progressive disease that, if left untreated, can result in death. The disease known as alcoholism is multifactorial, affecting both the physical and mental health of the patient. While alcohol abuse is a phenomenon that can be stopped, alcoholic disease cannot be completely cured. In both cases, however, the side effects arising during the state of alcoholism can be minimized. Alcohol abuse leads to disorders of the circulatory, digestive, nervous, and respiratory systems. Studies indicate that BPC-157 peptide allows for minimizing the pathological effects accompanying the treatment of alcohol addiction.

BPC-157 Therapy in Treating the Effects of Alcohol Addiction

Studies demonstrate the beneficial effect of BPC-157 peptide on alcohol-related gastric changes that occurred during addiction to or abuse of alcohol. Abuse of high-proof beverages often leads to the development of gastric ulcers, and as is known from previous articles, systematic use of the peptide leads to their elimination and gastroprotection, creating a safe protective barrier for the stomach. In the circulatory system, which is strained by the effects of alcohol and experiences elevated blood pressure, this system is restored to normal functioning through BPC-157, leading to proper blood flow. BPC-157 allows for a reduction in chronic portal hypertension caused by alcohol. Additionally, the use of the peptide during therapy, where a relapse may occur, counteracts further chronic damage to the stomach caused by chronic alcohol consumption. The action of BPC-157 allows for faster recovery during acute alcohol poisoning. Research also shows that alcohol abuse affects the volume of grey matter in the brain, causing its reduction. The action of BPC-157 peptide causes an increase in serotonin synthesis in the grey matter and antagonizes serotonin syndrome.

Treatment of the Effects of Drug Addiction

Drug Addiction

Drug addiction is defined as a progressive disease leading to the deterioration of the body. A characteristic feature of the disease is the necessity of taking a specific intoxicating substance, causing psychological and physical dependence. An addicted person feels an internal compulsion to increase the doses of psychoactive substances consumed, losing control over their use. Unwanted symptoms of drug addiction include, among others, increased tolerance to intoxicating substances, reaching for drugs despite noticing unpleasant health, psychological, and social consequences, or the appearance of an abstinence syndrome such as trembling of hands and muscles, excessive sweating, irritability, hallucinations, depression, deterioration of concentration, and anxiety.

Withdrawal Syndrome

Withdrawal syndrome is a phenomenon occurring at the moment when an addicted person ceases taking specific substances or when the dose of that substance is reduced. Ailments that may appear in connection with the occurrence of withdrawal syndrome include, among others, slowing of heart rate, a drop in blood pressure, a decrease in cortisol levels, a decrease in adrenaline levels, or a decrease in dopamine levels as the happiness hormone. Additionally, weight gain and disturbances in attention, concentration, and memory also occur. The symptoms of the syndrome are felt most strongly during the first months after discontinuing the substance; over time, the longer the period of abstinence from the substance, the weaker the symptoms of the withdrawal syndrome become.

BPC-157 Therapy in Treating the Effects of Drug Addiction

Laboratory studies show that in the case of amphetamine use in combined treatment with BPC-157 peptide, it will exhibit a reduced degree of action. During the studies, it was observed that at the moment of the strongest stereotypical excitability behavior, additional treatment with amphetamine in the presence of the peptide reduces the degree of its action in a rapid and long-lasting manner. The use of BPC-157 during withdrawal syndrome, where symptoms such as trembling, shaking, and even violent convulsions, panic jumps, and flight may appear, causes a reduction of these effects. The action profile of BPC-157 in treating amphetamine addiction involves reducing the activation of the dopaminergic system in the corpus striatum, which causes immediate interference with amphetamine activity. In a state of elevated dopamine levels with amphetamine involvement, BPC-157 prevents its release and the resulting consequences.

BPC-157 Therapy in Relation to Local Anesthetics

Local Anesthetics

Local anesthetic drugs in their therapeutic profile act locally by paralyzing nerve fibers and blocking pain stimuli. The anesthetic effect is a reversible effect, maintained for a specific period of time depending on physicochemical properties. The most common adverse effects of local anesthetic drugs include numbness of the tongue and mouth, metallic taste, drowsiness, visual disturbances, vasodilation, and tinnitus. In the case of higher doses, adverse effects are characterized by dangerous, life-threatening symptoms such as convulsions, loss of consciousness, depression of the respiratory and circulatory centers, bradycardia, and even cardiac arrest. BPC-157 peptide therapy allows for the reversal of unwanted pathological effects arising from the abuse of local anesthetics.

BPC-157 as an Antidote to Local Anesthetics

Presenting BPC-157 peptide as an antidote, using lidocaine as an example, allows for the classification of its action profile, leading to depolarization in non-transfected HEK 293 cells. Administration of BPC-157 can attenuate the development of adverse effects induced by lidocaine. As is known, BPC-157 largely interacts with the NO system. Administration of BPC-157 peptide shortens the duration of lidocaine action. BPC-157 also counteracts the side effects caused by lidocaine-induced effects such as cardiac arrhythmias and elimination of the risk of seizures in connection with its action. Furthermore, BPC-157 may have a particular influence on the vascular system and therefore on the time lidocaine remains in the body through vasodilation and local vascularization.

BPC-157 Therapy in Relation to Opioid Substances

Opioid Drugs

Opioids are used in pain management and belong to one of the main groups in this therapy. Rational selection of doses and appropriate use of opioid drugs, through knowledge of their mechanisms of action, allows for the avoidance of adverse effects associated with their use. Due to their action profile, they directly affect three types of opioid receptors μ (MOR), δ (DOR), and κ (KOR). Weak opioid drugs include codeine, dihydrocodeine (DHC), and tramadol. Strong opioids include morphine, fentanyl, buprenorphine, methadone, tapentadol, oxycodone, and pethidine. Using the strong opioid drug morphine as an example, we can indicate the therapeutic influence of BPC-157 in cases of abuse or poisoning with these drugs.

BPC-157 Therapy in Treating Opioid Drug Poisoning

Using morphine as an example, in reference to conducted studies, BPC-157 induces the release of serotonin in specific nigrostriatal areas of the brain and influences the serotonergic and dopaminergic systems. This produces beneficial effects within the overstimulated or dopaminergically damaged serotonergic and GABAergic systems. The action of BPC-157 leads to analgesia, consisting of the absence of perception of only pain stimuli from morphine, without indirect effects. The action of BPC-157 during the treatment of opioid drug poisoning can be observed even at very small doses. The peptide induces an enhancement of the antinociceptive action of morphine, indicating that BPC-157 acts primarily through the central dopaminergic system, leading to a reduction of unwanted effects caused by opioid drugs, assistance during poisoning with them, or protection against their harmful action.

Bibliography

1.Sikiric.P, Seiwerth.S, Rucman.R, Turkovic.B, Rokotov.D, Brcic.L, Toxicity by NSAIDs. Counteraction by Stable Gastric Pentadecapeptide BPC 157 Predrag. 2013; 19: 76-83; DOI:10.2174/1381612811306010076

2.Sikiric.P, Seiwerth.S, Rucman.R, Kolenc.D, Vuletic.L, Drmic.T, Grgic.D, Strbe.S, Zukanovic.G, Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. 2016; 14(8): 857–865; DOI:10.2174/1570159X13666160502153022,

3.Lozic.M, Stambolija.V, Krezic.I, Dugandzic.A, Zivanovic-Posilovic.G, Gojkovic.S, In relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro. 2020; DOI:10.1155/2020/6805354

4.Jelovac.N, Sikirid.P, Petek.M, Perovid.D, Marovid.A, Seiwerth.S, A Novel Pentadecapeptide, BPC 157, Blocks the Stereotypy Produced Acutely by Amphetamine and the Development of Haloperidol-Induced Supersensitivity to Amphetamine; DOI:10.1016/S0006-3223(97)00277-1

5.Sikiric.P, Seiwerth.S, Blagaic.B, Brcic.L, Zoricici.M, Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease. 2006; 214–221, DOI:10.1007/s10787-006-1531-7